FRM
YMAB

Fox Run Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Fox Run Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26,151
Closed -$178K – 1035
2023
Q2 		$178K Buy
+26,151
New +$196K 0.05% 596

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fox Run Management's YMAB Position: Q3 2023 in Review

Fox Run Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2023, closing a stake of 26,151 shares — an estimated $178K sold.

Fox Run Management first reported a position in YMAB in Q2 2023 and held it in 1 quarter. The position peaked at $178K in Q2 2023. 98 funds tracked by Wall St. Rank hold YMAB as of Q3 2023.

  • Fox Run Management reported no remaining Y-mAbs Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Fox Run Management sold 26,151 Y-mAbs Therapeutics shares in Q3 2023, an estimated $178K.
  • Fox Run Management first reported a position in Y-mAbs Therapeutics in Q2 2023 and held it in 1 quarter.
  • Fox Run Management's Y-mAbs Therapeutics position peaked at $178K in Q2 2023.
  • 98 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2023.

Based on Fox Run Management's 13F filing for Q3 2023, filed 7 Nov 2023.